Medicaid Headwinds | Centene faces delayed Medicaid margin recovery, impacting near-term outlook but analysts maintain long-term optimism despite 150-200 basis points of pressure |
Financial Resilience | Explore Centene's robust performance with FY2024 EPS estimates at $6.85 and FY2025 at $7.60, showcasing strength amid sector challenges |
Market Position | Delve into Centene's $38.5B market cap and strategic focus on government-sponsored healthcare programs, positioning it for potential long-term growth |
Analyst Perspectives | Barclays maintains an Overweight rating with a price target range of $90-$97, reflecting confidence in Centene's ability to navigate industry pressures |
Centene Corporation operates as a healthcare enterprise that provides programs and services to under-insured and uninsured families, commercial organizations, and military families in the United States. The company operates through Medicaid, Medicare, Commercial, and Other segments. The Medicaid segment offers health plan coverage, including medicaid expansion, aged, blind, disabled, children's health insurance program, foster care, medicare-medicaid plans, long-term services and support. This segment also provides healthcare products. The Medicare segment offers special needs and medicare supplement, and prescription drug plans. The Commercial segment provides health insurance marketplace product for individual, small, and large group commercials. It also operates clinical healthcare and pharmacies, as well as offers dental and speech therapy services. In addition, the company engages in the government contracts business under the TRICARE program and other healthcare related government contracts. It provides services through primary and specialty care physicians, hospitals, and ancillary providers. Centene Corporation was founded in 1984 and is headquartered in Saint Louis, Missouri.
Metrics to compare | CNC | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCNCPeersSector | |
---|---|---|---|---|
P/E Ratio | 13.6x | 3.4x | −0.6x | |
PEG Ratio | 1.45 | −0.30 | 0.00 | |
Price/Book | 1.4x | 3.7x | 2.6x | |
Price / LTM Sales | 0.3x | 0.9x | 3.2x | |
Upside (Analyst Target) | 21.5% | 0.3% | 48.5% | |
Fair Value Upside | Unlock | 11.8% | 7.8% | Unlock |